Introduction
Since its introduction in 1946 haemodialysis has been the mainstay of medical management of end stage renal failure. ' Unfortunately, for some patients, particularly the elderly and young, haemodialysis is unsuitable. Continuous ambulatory peritoneal dialysis was proposed as a method of treating these difficult patients,' but since its introduction in the United Kingdom in 1978 its application has extended dramatically. 3 Continuous ambulatory peritoneal dialysis allows a more sustained control of uraemia and a greater reduction in requirements for transfusions than haemodialysis. As uraemic immunodepression and preoperative blood transfusions contribute to the success of grafting4 5 patients receiving continuous ambulatory peritoneal dialysis may, theoretically, be at increased risk of graft failure after transplantation.6 If this proved correct it would constitute a major disadvantage for patients treated with continuous ambulatory peritoneal dialysis.
As in Newcastle upon Tyne a large proportion of our patients are treated with continuous ambulatory peritoneal dialysis while awaiting transplantation, we were able to test whether this risk is a real one by comparing results of renal transplantation in patients treated with conventional haemodialysis with those treated with continuous ambulatory peritoneal dialysis.
Patients and methods
Continuous ambulatory peritoneal dialysis was 
GRAFT REJECTION IN FIRST CADAVER RECIPIENTS
To examine more closely the possible influence of continuous ambulatory peritoneal dialysis on renal allograft rejection, only first cadaver recipients were studied. After exclusion of grafts lost as a result of non-immunological reasons and four patients who were treated with cyclosporin there were 152 patients, 107 of whom had received haemodialysis and 45 continuous ambulatory peritoneal dialysis before transplantation and who were treated by the same postoperative regimen of azathioprine and prednisolone. Actuarial analysis showed no significant effect of type of dialysis on loss of renal allografts from rejection (fig 2) . The number of HLA-DR matches was smaller and the number of preoperative transfusions and duration of dialysis were significantly greater for those patients This study confirms an earlier report that excellent survival of allografts can be expected in patients given continuous ambulatory peritoneal dialysis who have received preoperative transfusions and who are treated with azathioprine and prednisolone." Survival of patients was not significantly different in the two groups, and since introduction of a policy of avoiding transplantation within three weeks of a confirmed episode of peritonitis no deaths have occurred as a result of continuous ambulatory peritoneal dialysis peritonitis in allograft recipients. Although there were slightly more graft failures due to nonimmunological reasons in patients who received continuous ambulatory peritoneal dialysis, the number was not significantly different from those treated with haemodialysis.
Detailed examination of patients' background showed a remarkable similarity in the age and distribution of sex in the two groups, possibly reflecting the policy at this centre of using continuous ambulatory peritoneal dialysis as an effective first line method of treating end stage renal failure. The high proportion of transplants that were HLA-B antigen matched is explained by our deliberate matching policy based on previously shown benefits in recipients who have had transfusions.7 The increased proportion of HLA-DR matches among patients who received continuous ambulatory peritoneal dialysis may also reflect a recent policy of accepting HLA-DR matched kidneys that coincided with a greater proportion of potential transplant recipients who had previously received continuous ambulatory peritoneal dialysis.
Continuous ambulatory peritoneal dialysis may reduce requirements for transfusions in renal failure by reducing loss of blood while receiving haemodialysis and more efficient removal of harmful "middle molecules" thought to sustain anaemia. 3 A recent report, however, does not show any difference in the survival of red cells in blood transfused to patients receiving continuous ambulatory peritoneal dialysis or haemodialysis.24 In this study although patients treated with continuous ambulatory peritoneal dialysis received significantly fewer transfusions in total than those treated with haemodialysis, the differences may only reflect the relative total duration of dialysis. '5 Haemodialysis preceded continuous ambulatory peritoneal dialysis as treatment for renal failure, therefore, most patients given transplants from our waiting list had received haemodialysis, and the duration of dialysis exceeded that of those given continuous ambulatory peritoneal dialysis. Recent studies have shown that increased duration of dialysis and number of preoperative blood transfusions improve allograft survival," 25 a factor that might favour patients treated with haemodialysis. After allowing for these background variables in the multiple regression modell3 continuous ambulatory peritoneal dialysis proved to be at least as good as, and possibly superior to, haemodialysis in preparing patients for long term allograft survival.
Continuous ambulatory peritoneal dialysis was first proposed as a method of treating patients who were unsuitable for haemodialysis and was adopted by several centres, predominantly for these so called "high risk" patients.2 Inclusion of a high proportion of such patients in an analysis of continuous ambulatory peritoneal dialysis and outcome of transplantation may explain differences from our study, in which continuous ambulatory peritoneal dialysis was, from the outset, used as a first line method of dialysis. Such "centre effect"26 differences in the selection and management of renal transplant recipients should be borne in mind when interpreting possible risk factors for graft survival.
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In this study of a homogenous population of transplant recipients who had received transfusions, treated with conventional immunosuppressive drugs, continuous ambulatory peritoneal dialysis was not found to be a risk factor for the survival of patients or grafts, and its continued use in the preparation of patients with end stage renal failure for transplantation is recommended.
Introduction
An increasing number of patients with end stage renal failure throughout the world have been treated with continuous ambulatory peritoneal dialysis since its introduction in 1976. The 1984 report from the European Dialysis and Transplant Association showed that 5228 patients in Europe had been treated with continuous ambulatory peritoneal dialysis up to December 1983. The United Kingdom accounted for almost a third of this total.' The risk of septic complications secondary to the presence of an
